[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multi-antibiotic-resistance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multi-antibiotic-resistance":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100420764","phase-1-fmt-for-the-decolonization-of-carbapenem-resistant-enterobacteriaceae-100420764",false,"NCT04759001","FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae","Faecal Microbiota Transplantation to Eradicate Gut Colonisation From Carbapenem-resistant Enterobacteriaceae: a Randomised Controlled Trial","FMT-CRE","Inclusion criteria\n\n* 18 years old or older\n* Current evidence of gut colonisation (diagnosed with rectal swab) by CRE\n* Ability to give their consent to be included in the study.\n\nExclusion criteria\n\n* Another known gastrointestinal infection apart from C. difficile infection\n* Known active gastrointestinal disorders (e.g. infectious gastroenteritis, coeliac disease, inflammatory bowel disease, irritable bowel syndrome, chronic pancreatitis, biliary salt diarrhoea)\n* Previous colorectal surgery or cutaneous stoma\n* Food allergies\n* Current or recent (\\\u003C2 weeks) therapy with drugs that could possibly alter gut microbiota (e.g. antimicrobials, probiotics, proton pump inhibitors, immunosuppressants, metformin)\n* Decompensated heart failure or heart disease with ejection fraction lower than 30%\n* Severe respiratory insufficiency\n* Psychiatric disorders\n* Pregnancy\n* Unable to give informed consent","ALL","18 Years","90 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Rates of antimicrobial resistance are increasing worldwide. There is increasing evidence that physiological gut microbiota is a large reservoir of antibiotic-resistance genes. Healthy gut microbiota is known to prevent the colonization of the gastrointestinal tract by pathogens, the so-called mechanism of colonization resistance, but this protective mechanism can be altered by therapies that impair gut microbiota, including antibiotics or chemotherapeutics, with consequent colonisation of gut pathogens, including multi-drug resistant bacteria (MDRB). MDRB carriers represent an epidemiological threat to other hospitalized patients and to the whole community, but are also at risk of developing clinical consequences of this colonization, including bloodstream infections from these pathogens. Fecal microbiota transplantation (FMT) has shown high efficacy in the eradication of recurrent C. difficile infection, and initial evidence suggests that this procedure could be useful in eradicating also MDRB, mainly carbapenem-resistant Enterobacteriaceae.\n\nHowever, current evidence is mostly limited to case reports and case series, and to a single randomised trial, which was stopped early and did not draw clear conclusion. In a systematic review of 21 studies and 192 patients, eradication rates ranged from 0% to 100%, and authors concluded that larger, well designed randomised controlled trials are needed to further explore this therapy.\n\nThe aim of this study is to investigate the efficacy of FMT, compared with placebo FMT, in eradicating gut colonisation from MDRB, focusing on CRE. The investigators will randomize patients colonized by CRE (diagnosed by rectal swab) to FMT from healthy donors or placebo, by colonoscopy. Then, patients will be followed up, rectal swabs will be repeated, and stool samples for culture and microbiome analysis will be collected, up to 3 months after FMT.",[29,30],"Enterobacteriaceae Infections","Multi-antibiotic Resistance",[32,33,34],"Fecal microbiota transplantation","Enterobacteriaceae","Multi-drug resistant bacteria","RECRUITING","2026-03-17",{"date":38,"type":39},"2026-03-19","ACTUAL",{"date":41,"type":39},"2021-02-18",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100388254","isolation-of-human-recombinant-therapeutic-monoclonal-anti-pseudomonas-antibodies-100388254","NCT04335383","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial","ABAC-IBS","Inclusion Criteria:\n\n* Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)\n* Patient with weight ≥ 32kg.\n* With a follow-up visit at Grenoble University Hospital with a blood sampling for its care\n* Having given its written no objection to participate in the prospective phase of this project\n\nExclusion Criteria:\n\n* Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)",{"count":57,"type":22},30,"OBSERVATIONAL","Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.\n\nThe aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.",[61,30],"Pseudomonas Aeruginosa",[63,64],"Pseudomonas aeruginosa","monoclonal antibody","2025-11-17",{"date":67,"type":39},"2025-11-20",{"date":69,"type":39},"2020-10-05",{"date":71,"type":22},"2026-10",{"name":73,"class":46},"University Hospital, Grenoble",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100500064","phase-1-fmt-to-eradicate-intestinal-colonization-by-carbapenem-resistant-enterobacteriaceae-100500064","NCT05791396","FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae","Efficacy and Mechanisms of Fecal Microbiota Transplantation to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae","FMT_CRE","Inclusion Criteria:\n\n* \\>18 years;\n* CRE diagnosed with rectal swab \\\u003C15 days before evaluation;\n* Ability to undergo study procedures and to give informed consent.\n\nExclusion Criteria:\n\n* Active chronic gastrointestinal disorders;\n* Previous colorectal surgery;\n* Major comorbidities;\n* Pregnancy\u002Fbreastfeeding;\n* Psychiatric disorders.","85 Years",{"count":84,"type":22},36,[25,26],"Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 infections and 33.000 attributable deaths from multi-drug-resistant bacteria (MDRB) have occurred in Europe in 2015. The gastrointestinal tract is a large reservoir for MDRB, and the gut microbiota can harbor a collection of AR genes, called gut resistome. Preliminary nonrandomized evidence suggests that fecal microbiota transplant (FMT) could be a promising treatment option to eradicate MDRB, but established evidence, as well as mechanisms that underpin this therapeutic pathway, are still unavailable. Leveraging our expertise in FMT (OU1), microbiome (OU2) and MDRB (OU3), we aim to evaluate the efficacy of FMT (from donors with limited presence of AR genes) in eradicating intestinal MDRB through a randomized controlled trial and identifying microbial features that are associated with clinical efficacy and clearance of AR genes",[29,30],[32,33,34],"2025-03-10",{"date":91,"type":39},"2025-03-12",{"date":93,"type":39},"2024-02-08",{"date":95,"type":22},"2026-04",{"name":45,"class":46}]